Eravacycline
- Generic Name
- Eravacycline
- Brand Names
- Xerava
- Drug Type
- Small Molecule
- Chemical Formula
- C27H31FN4O8
- CAS Number
- 1207283-85-9
- Unique Ingredient Identifier
- 07896928ZC
- Background
Eravacycline, known as Xerava by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and facultative bacteria. This includes most of those bacteria resistant to cephalosporins, fluoroquinolones, β-lactam/β-lactamase inhibitors, multidrug-resistant strains, and carbapenem-resistant Enterobacteriaceae, and the majority of anaerobic pathogens . It was first approved by the FDA on August 27, 2018 . Eravacycline has demonstrated superior potency to that of antibiotics that are currently being marketed for intraabdominal infections .
- Indication
Eravacycline is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older .
- Associated Conditions
- Intraabdominal Infections
A Study on the Combination Therapy of Eravacycline for Treating Carbapenem-Resistant Acinetobacter Baumannii Pneumonia
- Conditions
- PneumonitisAcinetobacter Baumannii
- Interventions
- First Posted Date
- 2024-11-01
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT06670872
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
Therapeutic Options for CRAB
- Conditions
- Infections, BacterialSepsis Bacterial
- Interventions
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Clinical Hospital Centre Zagreb
- Target Recruit Count
- 108
- Registration Number
- NCT06440304
- Locations
- 🇭🇷
University Hospital Centre Zagreb, Zagreb, Croatia
Eravacycline Combination Therapy for MRAB
- Conditions
- Pulmonary InfectionPneumonia, BacterialAcinetobacter Baumannii
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Fujian Medical University Union Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06282835
- Locations
- 🇨🇳
Fujian Medical University Union hospital, Fuzhou, Fujian, China
Efficacy and Safety of the Combination Therapy Based on Eravacycline in Immunocompromised Hosts With MDROS Infection
- Conditions
- Immune Dysregulation Disorder
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Sichuan Provincial People's Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06223100
Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia
- First Posted Date
- 2022-09-13
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- West Virginia University
- Target Recruit Count
- 55
- Registration Number
- NCT05537896
- Locations
- 🇺🇸
Aaron Cumpston, Morgantown, West Virginia, United States
A Safety and PK Study of IV Eravacycline
- First Posted Date
- 2018-10-04
- Last Posted Date
- 2021-12-03
- Lead Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT03696550
- Locations
- 🇺🇸
Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States
🇺🇸University Hospitals Cleveland Medical Center, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States
🇺🇸Ronald Reagan University of California Los Angeles Medical Center, Los Angeles, California, United States
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections
- Conditions
- Complicated Urinary Tract Infections
- Interventions
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2022-01-06
- Lead Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Target Recruit Count
- 1205
- Registration Number
- NCT03032510
Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections
- Conditions
- Complicated Intra-abdominal InfectionsComplicated Appendicitis
- Interventions
- First Posted Date
- 2016-05-27
- Last Posted Date
- 2022-01-06
- Lead Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT02784704
A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With End Stage Renal Disease and Healthy Subjects
- First Posted Date
- 2014-05-09
- Last Posted Date
- 2021-12-17
- Lead Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02135276
A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects
- First Posted Date
- 2014-05-09
- Last Posted Date
- 2021-12-17
- Lead Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02135302
- Locations
- 🇺🇸
Davita Clinical Research, Lakewood, Colorado, United States
🇺🇸New Orleans Center for Clinical Research, Knoxville, Tennessee, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.